Ology Bioservices to Develop Vaccine Candidate Against Malaria for The Global Health Initiative Fund.

Ology Bioservices will develop the large-scale, process development and manufacturing plan and supply the AnAPN1 vaccine candidate for use in ongoing pre-clinical studies and to prepare for subsequent clinical testing.

The new grant from the Global Health Innovative Technology, or GHIT, Fund will further development of processes to move the vaccine from the experimental stage to human trials and, ultimately, a clinical treatment. The GHIT Fund is an international public-private partnership spearheaded by the Government of Japan, the Bill and Melinda Gates Foundation, Wellcome Trust and a group of pharmaceutical companies.

Learn more about it at the University of Florida website

2018-07-14T21:27:07+00:00